Literature DB >> 17915099

Malignancy and rheumatoid arthritis.

Johan Askling1.   

Abstract

The occurrence of cancer is not an infrequent event in patients with rheumatoid arthritis (RA). Indeed, following diagnosis of RA at a typical age (55 years), one in five patients will be diagnosed with cancer. In the vast majority of such cases, the cancer has nothing to do with RA or its treatment; rather, it represents the "background" risk applicable to all humans. In some cases, the cancer occurs as a result of factors also associated with the risk of developing RA (eg, smoking), even though no direct link exists between the cancer and the RA. In a fraction of cases, however, the cancer is causally associated with the RA disease or its treatments. This review summarizes our current understanding of the occurrence of cancer in RA, possible links to RA disease and to traditional and newer RA treatments.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17915099     DOI: 10.1007/s11926-007-0067-1

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  40 in total

Review 1.  Smoking as a trigger for inflammatory rheumatic diseases.

Authors:  Lars Klareskog; Leonid Padyukov; Lars Alfredsson
Journal:  Curr Opin Rheumatol       Date:  2007-01       Impact factor: 5.006

2.  Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.

Authors:  Eva Baecklund; Anastasia Iliadou; Johan Askling; Anders Ekbom; Carin Backlin; Fredrik Granath; Anca Irinel Catrina; Richard Rosenquist; Nils Feltelius; Christer Sundström; Lars Klareskog
Journal:  Arthritis Rheum       Date:  2006-03

3.  Risk of malignancy among patients with rheumatic conditions.

Authors:  E Thomas; D H Brewster; R J Black; G J Macfarlane
Journal:  Int J Cancer       Date:  2000-11-01       Impact factor: 7.396

4.  Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.

Authors:  J Askling; C M Fored; E Baecklund; L Brandt; C Backlin; A Ekbom; C Sundström; L Bertilsson; L Cöster; P Geborek; L T Jacobsson; S Lindblad; J Lysholm; S Rantapää-Dahlqvist; T Saxne; L Klareskog; N Feltelius
Journal:  Ann Rheum Dis       Date:  2005-04-20       Impact factor: 19.103

5.  Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis.

Authors:  Eva Baecklund; Carin Backlin; Anastasia Iliadou; Fredrik Granath; Anders Ekbom; Rose-Marie Amini; Nils Feltelius; Gunilla Enblad; Christer Sundström; Lars Klareskog; Johan Askling; Richard Rosenquist
Journal:  Arthritis Rheum       Date:  2006-12

6.  Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors.

Authors:  Eliza F Chakravarty; Kaleb Michaud; Frederick Wolfe
Journal:  J Rheumatol       Date:  2005-11       Impact factor: 4.666

Review 7.  NF-kappaB: tumor promoter or suppressor?

Authors:  Neil D Perkins
Journal:  Trends Cell Biol       Date:  2004-02       Impact factor: 20.808

8.  A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.

Authors:  Srinivasan Madhusudan; Martin Foster; Sethupathi R Muthuramalingam; Jeremy P Braybrooke; Susan Wilner; Kulwinder Kaur; Cheng Han; Susan Hoare; Frances Balkwill; Denis C Talbot; Trivadi S Ganesan; Adrian L Harris
Journal:  Clin Cancer Res       Date:  2004-10-01       Impact factor: 12.531

9.  The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.

Authors:  Frederick Wolfe; Kaleb Michaud
Journal:  Arthritis Rheum       Date:  2007-05

Review 10.  TNF-alpha in promotion and progression of cancer.

Authors:  Frances Balkwill
Journal:  Cancer Metastasis Rev       Date:  2006-09       Impact factor: 9.264

View more
  8 in total

Review 1.  Review of clinical registries of psoriatic arthritis: lessons learned?: value for the future?

Authors:  Dafna D Gladman; Vinod Chandran
Journal:  Curr Rheumatol Rep       Date:  2011-08       Impact factor: 4.592

Review 2.  [Gastrointestinal tumors. Clinical manifestations of paraneoplastic rheumatic symptoms].

Authors:  W-J Mayet
Journal:  Z Rheumatol       Date:  2011-09       Impact factor: 1.372

3.  Breast cancer and systemic sclerosis: a clinical description of 21 patients in a population-based cohort study.

Authors:  Tim Y-T Lu; Catherine L Hill; Eliza K Pontifex; Peter J Roberts-Thomson
Journal:  Rheumatol Int       Date:  2008-02-16       Impact factor: 2.631

Review 4.  Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders.

Authors:  Grace Y Lam; Brendan P Halloran; Anthea C Peters; Richard N Fedorak
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

5.  Identification of the Main Active Components and Mechanism of Wang Bi Tablet in Treating Rheumatoid Arthritis Based on Integrative Pharmacology.

Authors:  Yuanyuan Jiao; Jia Xu; Hong Chen; Qiuyan Guo; Xiaofang Deng; Tong Zhang; Jingbo Zhang; Chenjing Shi; Ping Wang
Journal:  Front Pharmacol       Date:  2021-06-04       Impact factor: 5.810

6.  A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis.

Authors:  Allison L Smitten; Teresa A Simon; Marc C Hochberg; Samy Suissa
Journal:  Arthritis Res Ther       Date:  2008-04-23       Impact factor: 5.156

7.  Risk of lymphoma and solid cancer among patients with rheumatoid arthritis in a primary care setting.

Authors:  Christen Lykkegaard Andersen; Hanne Lindegaard; Hanne Vestergaard; Volkert Dirk Siersma; Hans Carl Hasselbalch; Niels de Fine Olivarius; Ole Weis Bjerrum; Peter Junker
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

Review 8.  The Complex Role of C-Reactive Protein in Systemic Lupus Erythematosus.

Authors:  Helena Enocsson; Jesper Karlsson; Hai-Yun Li; Yi Wu; Irving Kushner; Jonas Wetterö; Christopher Sjöwall
Journal:  J Clin Med       Date:  2021-12-13       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.